Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 12:18 pm Purchase | 2024-12-31 | 13G | Mural Oncology plc MURA | ACORN BIOVENTURES, L.P. | 1,286,079 7.600% | 208,857 (+19.39%) | Filing History |
| 2025-02-14 12:14 pm Purchase | 2024-12-31 | 13G | Puma Biotechnology, Inc. PBYI | ACORN BIOVENTURES, L.P. | 3,940,052 8.000% | 660,612 (+20.14%) | Filing History |
| 2024-11-14 12:12 pm Purchase | 2024-09-30 | 13G | Puma Biotechnology, Inc. PBYI | ACORN BIOVENTURES, L.P. | 3,279,440 6.700% | 344,944 (+11.75%) | Filing History |
| 2024-11-14 12:00 pm Purchase | 2024-08-09 | 13G | Mural Oncology plc MURA | ACORN BIOVENTURES, L.P. | 1,077,222 6.300% | 228,700 (+26.95%) | Filing History |
| 2024-10-09 4:01 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | ACORN BIOVENTURES, L.P. | 1,439,674 11.400% | 1,439,674 (New Position) | Filing History |
| 2024-08-13 4:43 pm Purchase | 2024-08-09 | 13G | Mural Oncology plc MURA | ACORN BIOVENTURES, L.P. | 848,522 5.000% | 848,522 (New Position) | Filing History |
| 2024-04-04 8:33 pm Purchase | 2024-03-25 | 13D | Q32 Bio Inc. QTTB | ACORN BIOVENTURES, L.P. | 803,425 6.700% | 803,425 (New Position) | Filing History |
| 2024-02-14 4:44 pm Purchase | 2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | ACORN BIOVENTURES, L.P. | 17,755,869 9.990% | 17,755,869 (New Position) | Filing History |
| 2024-02-13 5:16 pm Purchase | 2023-12-31 | 13G | OptiNose, Inc. OPTN | ACORN BIOVENTURES, L.P. | 802,801 9.900% | 44,870 (+5.92%) | Filing History |
| 2024-02-07 5:03 pm Sale | 2023-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 0 0.000% | -187,676 (Position Closed) | Filing History |
| 2024-02-06 4:01 pm Sale | 2023-12-31 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 1,946,762 4.200% | -1,096,411 (-36.03%) | Filing History |
| 2024-02-06 3:59 pm Purchase | 2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 2,761,825 6.300% | 2,761,825 (New Position) | Filing History |
| 2024-02-06 3:57 pm Purchase | 2023-12-31 | 13G | BioAtla, Inc. BCAB | ACORN BIOVENTURES, L.P. | 4,032,046 8.400% | 1,305,591 (+47.89%) | Filing History |
| 2024-02-06 3:54 pm Purchase | 2023-12-31 | 13G | Puma Biotechnology, Inc. PBYI | ACORN BIOVENTURES, L.P. | 2,934,496 6.200% | 194,561 (+7.10%) | Filing History |
| 2023-09-01 10:18 am Purchase | 2023-08-22 | 13G | Puma Biotechnology, Inc. PBYI | ACORN BIOVENTURES, L.P. | 2,739,935 5.800% | 2,739,935 (New Position) | Filing History |
| 2023-04-27 12:11 pm Purchase | 2023-04-20 | 13G | BioAtla, Inc. BCAB | ACORN BIOVENTURES, L.P. | 2,726,455 5.700% | 2,726,455 (New Position) | Filing History |
| 2023-04-03 1:46 pm Purchase | 2023-03-15 | 13G | Y-mAbs Therapeutics, Inc. YMAB | ACORN BIOVENTURES, L.P. | 2,326,528 5.300% | 2,326,528 (New Position) | Filing History |
| 2023-01-26 1:36 pm Purchase | 2022-12-31 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | ACORN BIOVENTURES, L.P. | 187,676 9.990% | 31,377 (+20.07%) | Filing History |
| 2023-01-26 1:30 pm Unchanged | 2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | 0 (Unchanged) | Filing History |
| 2023-01-26 1:28 pm Sale | 2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | -2,947,666 (-49.20%) | Filing History |